期刊文献+

超快速液相色谱-串联质谱法测定胎盘灌流液中拉米夫定的浓度 被引量:2

Determination of Lamivudine in Placental Perfusate by Employing Ultra Fast Liquid Chromatography with Tandem Mass Spectrometry
原文传递
导出
摘要 目的建立超快速液相色谱-串联质谱(UPLC-MS/MS)法检测胎盘灌流液中拉米夫定的浓度。方法以法莫替丁为内标,胎盘灌流液样本用乙腈沉淀蛋白处理,采用Shim-packXR—ODSIICIs柱(2.0mm×75mm,2.2μm)为分析柱,以甲醇和10mmol·L-1醋酸铵溶液为流动相进行梯度洗脱,流速为0.4mL·min-1,采用离子选择性电极离子源正离子模式,多反应监测进行定量分析。结果本法在1~2500ng·mL-1间线性良好,日内日间精密度〈10%,绝对回收率I〉72%。结论本方法快速可靠,结果准确,适用于生物样本中拉米夫定浓度的测定。 OBJECTIVE To develop a method for determining the concentration of lamivudine in placental perfusate by emplo- ying ultra fast liquid chromatography with tandem mass spectrometry (UFLC-MS/MS). METHODS Famotidine was used as the in- ternal standard. After protein precipitation with acetonitrile, the chromatography was performed on a Shim-pack XR-ODS II Cis column (2. 0 mm ×75 mm,2. 2μm) with mobile phase consisting of methanol and 10 mmol · L-1 ammonium acetate, gradient elution was used, and the flow rate was 0. 4 mL · min-1. Tandem mass spectrometric detection was conducted by using multiple reaction monito- ring (MRM) in positive ionization mode with an electrospray ionization interface. RESULTS The calibration curve of lamivudine was linear in the range of 1 -2 500 ng · mL-I. The intra- and inter-batch RSDs were less than 10%. The method recovery was more than 72%. CONCLUSION The method is rapid and accurate, which is suitable for the determination of lamivudine in placental perfusate.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第24期2158-2161,共4页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(81360108)
关键词 拉米夫定 超快速液相色谱-串联质谱法 胎盘灌流液 lamivudine UFLC-MS/MS placental perfusate
  • 相关文献

参考文献9

  • 1HUTSON J R, GARCIA-BOURNISSEN F, DAVIS A, et at. lhe human placental perfusion model:A systematic review and devel- opment of a model to predict in siva transfer of therapeutic drugs [ J ]. Clin Pharmacol Ther,2011,90 ( 1 ) :67-76.
  • 2NANOVSKAYA T N,PATRIKEEVA S, HEMAUER S,et al. Effect of albumin on transplacental transfer and distribution of rosiglita- zone and glyburide [ J ]. J Matern-Fetal Neo M, 2008,21 ( 3 ) : 197-207.
  • 3单秀清.反相高效液相色谱法测定人血浆中拉米夫定浓度[J].中国药师,2006,9(5):447-449. 被引量:7
  • 4张丽军,姚亚敏,孙建军,贾小芳,彭霞,卢洪洲.高效液相色谱-串联质谱法同时测定奈韦拉平、拉米夫定、司他夫定、齐多夫定和依非韦伦的血药浓度[J].中国临床药理学杂志,2010,26(2):133-136. 被引量:14
  • 5李周,丁存刚,葛庆华,周臻,刘笑芬.人血浆中拉米夫定、齐多夫定、奈韦拉平的LC-MS/MS法测定[J].中国医药工业杂志,2010,41(3):200-204. 被引量:6
  • 6VALLURU R K, PHANI B R, RAVI K, et al. High throughput LC-MS/MS method for simultaneous determination of zidovudine, lamivudine and nevirapine in human plasma[ J]. J Chromatog B, 2013, 23(921 ) :9-14.
  • 7HIREN N M, ARVIND G, ASHUTOSH P, et al. High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma [ J ]. J Chromatog B, 2007, 853 (2) : 320-332.
  • 8MANISH Y, PURAN S, SAILENDRA G, et al. Selective deter- ruination of antiretroviral agents tenofovir, emtricitabine, and lami- vudine in human plasma by a LC-MS/MS method for a bioequiva- lence study in healthy Indian subjects [ J ] . J Chromatog Sci, 2010, 48(2) : 704-713.
  • 9JOSEPH E R, BRANDON K, LANE R B, et al. Validation of a sensitive LC-MS/MS method for the determination of zidovudine and lamivudine in human plasma[ J]. Biomed Chromatogr, 2012, 26(1) : 12-20.

二级参考文献22

  • 1郑青敏,李晓明,江骥,胡蓓.建立液相与串联质谱联用(LC-MS/MS)测定拉米夫定的方法[J].药物分析杂志,2005,25(1):73-75. 被引量:6
  • 2许正锯,杨红,张启华,陈先礼,李树清,王崇国.乙型肝炎病毒基因型与拉米夫定疗效关系的研究[J].临床肝胆病杂志,2005,21(3):157-159. 被引量:11
  • 3刘蕾,徐先彬,李扬,封宇飞,李可欣,孙春华.HPLC-MS/MS同时测定人血浆中4种抗HIV感染药物的浓度[J].药物分析杂志,2007,27(5):681-685. 被引量:2
  • 4O'Brien ME, Clark RA, Besch CL, et al. Palterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort [J]. J Acquir Immune Defic Syndr, 2003 ;34:407 -414.
  • 5Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment [ J ]. Siciss HIV Cohort Study Lancet, 2001 ;358:1322 - 1327.
  • 6Holland DT, DiFrancesco R, Connor JD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004 : a requirement for therapeutic drug monitoring [ J ]. Ther Drug Monit, 2006 ;28:367 - 374.
  • 7Back D, Gatti G. Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions [ J ]. Aids, 2002;16 (Suppl. 1 ) :S5 -37.
  • 8Poirier JM, Robidou P, Jaillon P. Simple and simultaneous determination of the hiv - protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir anti saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transeriptase inhibitors efavirenz and nevirapine in human plasma by reversed - phase liquid chromatography [J]. Ther Drug Monit, 2005; 27: 186 - 192.
  • 9Mistri HN, Jangid AG, Pudage A. High throughput LC -MS/MS method for simultaneous quantification of lamivudine, siavudinc and nevirapine in human plasma [ J ]. J Chromatogr B Analyt Technol Biowed Life Sci, 2007 ;853:320 - 332.
  • 10Rouzes A, Berthoin K, Xuereb F, et al. Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high - performance liquid chromatography - mass spectrometry [J]. J Chromatagr B Analyt Technol Biomed Life Sci, 2004; 813,209 -216.

共引文献23

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部